Michael Linden, MD, PhD

Current Position:  Pathology Residency, University of Washington

T32 Support: 2002 - 2004

Education:

1994 – 1998, B.A., St. Mary’s University, Winona, MN
1998 – 2004, Ph.D., University of Minnesota
1998 – 2006, M.D., University of Minnesota

Project: Mike’s research focused on the study of multiple myeloma (MM), an incurable form of cancer, characterized by the proliferation of malignant plasma cells (PCs) in the bone marrow.  Over the two years of his training, he worked on a project that sought to increase the prevalence of plasma cell neoplasia in the mouse using tissue and developmentally restricted transcriptional regulators to alter expression of anti-apoptotic and oncogenic genes. Together with other researchers, he developed a mouse whose plasma cells were resistant to apoptosis; these mice developed significant plasma cell disease. The hypothesis had been to cross the mouse to a separate group of mice that have altered expression of growth-promoting oncogenes, expecting that these crosses will result in progeny that develop plasma cell tumors. The ultimate goal was to generate a mouse model of multiple myeloma.

Publications:

Croonquist PA, Linden MA, Zhao F, Van Ness, BG.  Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-Ras-activating mutations, and coculture with bone marrow stromal cells.  Blood 2003; 102:2581-92.

Linden MA, Kirchhof N, Carlson CS, Van Ness BG.  Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies.  Blood  2004;103:2779-86.

Cheung WC, Kim JS, Linden MA, Van Ness BG, Polakiewicz R, Janz S.  Novel targeted deregulation of c-Myc and Bcl-XL causes plasma cell neoplasms in mice.  J Clinical Investigation  2004; 113:1763-1774.

Linden MA, Kirchof N, Kvitrud MA, Van Ness BG.  ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-XL transgenic mice.  Leuk Res   2005; 29(4):435-44.

Dunn TB. Linden MA. Vercellotti GM. Gruessner RW. Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clinical Transplantation 2006; 20(1):132-5.

Last updated 2-18-2008